You are here:-Community manager
Community manager

About Community manager

This author has not yet filled in any details.
So far Community manager has created 86 blog entries.

Upcoming REVIVE webinars

Drug Discovery of Antibiotics: The Importance of Physicochemical Properties Date: 4 December 2018 Time: 17:00-18:30 CEST (find your time zone here) Speaker: Heinz Moser This is a follow-up webinar to Heinz Moser's presentation at the GARDP-CARB-X co-organized "Antibiotic Bootcamp for Developers: Medicincal Chemistry" at the ESCMID/ASM Conference on Drug Development, Lisbon, 4-7 September 2018. Watch the presentation here. Register for the webinar Development of Antibacterial Drug Enhancer Combinations and Non-traditional Products Date: 29 January 2019 Time: 17:00-18:30 CEST (find your time zone here) Speakers: Ian Friedland, Sumathi Nambiar, Mair Powell, David Shlaes This webinar is

Upcoming REVIVE webinars 2018-11-14T16:00:26+00:00

The AMR Studio – A podcast by the Uppsala Antibiotic Center

The Uppsala Antibiotic Center launches their newest outreach project, "The AMR Studio", with the occasion of the World Antibiotic Awareness Week 2018.The AMR Studio is a podcast dedicated to highlighting the multidisciplinary research on antimicrobial resistance that is happening around the world. Formatted around interviews with professionals working in all aspects of the topic, they aim to bring the global and trans-sectorial nature of the fight against antimicrobial and antibiotic resistance to anyone with an interest. In this first episode The AMR Studio features a short introduction on antibiotics and antibiotic/antimicrobial resistance during an in-depth interview with the management team of

The AMR Studio – A podcast by the Uppsala Antibiotic Center 2018-11-12T14:09:41+00:00

More than one model to stimulate antimicrobial drug development

     By Lord Jim O'Neill. When I first started leading the AMR Review in 2014, I soon came to the conclusion that, if the current model wasn’t delivering new antimicrobial drugs, the solution was obvious: launch a new public purpose-focused entity dedicated to developing and producing new antimicrobials. When I shared this hunch with others, I was advised that it couldn’t be done without the major pharmaceutical companies, as they were the only ones with the expertise to produce and distribute drugs. I let this idea drop from my mind. At the time, I wasn’t aware of GARDP, and at

More than one model to stimulate antimicrobial drug development 2018-11-14T09:57:02+00:00

Making Safety a Part of Drug Design

Speaker: Claire Sadler, Senior Toxicologist, ApconiX, UKModerator: Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna, Austria* This presentation was also part of the GARDP and CARB-X co-organized session 'Antibiotic Bootcamps for Developers: Preclinical Toxicology' at the ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance *In this webinar, Claire Sadler discussed the toxicological challenges and pitfalls of antibiotic discovery programs. Potential safety risks are the major reason for terminating a program in early phases of antibiotic drug development. This webinar will help identifying the most common toxicology risks associated with antibiotic discovery and discuss potential mitigating strategies.We hosted this live

Making Safety a Part of Drug Design 2018-11-14T15:38:08+00:00

Bootcamp: Preclinical Toxicology (ESCMID/ASM 2018)

Antibiotic Bootcamps for Developers: Preclinical Toxicology ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 4-7 September 2018, Lisbon A collaborative project of GARDP and CARB-X Chair person: Ursula Theuretzbacher Speakers: Terry Miller, Claire Sadler, Ryan Cirz Roundtable discussion: Terry Miller, Claire Sadler, Ryan Cirz, Ursula Theuretzbacher Introduction Pitfalls in Preclinical Development from the Regulatory Perspective (FDA) (Terry Miller) Making Safety a Part of Drug Design (Claire Sadler) Real life story of unexpected toxicity - Lessons to learn (Ryan Cirz) Roundtable discussion On 13 November, Claire Sadler will join us for a live webinar with Q&A session.

Bootcamp: Preclinical Toxicology (ESCMID/ASM 2018) 2018-10-12T07:42:13+00:00

FDA’s Plan to Combat Antibiotic Resistance

On Friday, Sept. 14, 2018, at 10 a.m. EDT, The Pew Charitable Trusts hosts Dr. Scott Gottlieb, commissioner of the U.S. Food and Drug Administration, as he announces the agency’s plans to combat antibiotic resistance. Following Gottlieb’s remarks, a panel of FDA senior officials will further explore the agency’s new and ongoing activities to support antibiotic innovation and ensure that antimicrobial drugs are used according to good stewardship practices in human medicine and animal agriculture. Click here to find more information and to watch the live webcast on Friday, September 14.

FDA’s Plan to Combat Antibiotic Resistance 2018-09-11T13:13:40+00:00

A Discussion with Chris Lipinski and Barry Bunin

On September 13th, 2018, Collaborative Drug Discovery (CDD) will host a webinar with Christopher Lipinski and Barry Bunin. The discussed topics will include: Going beyond the Rules of 5 New technologies to better assess the quality of screening data Experimental culture and sociology as a factor in clustering of results Plus topics you would not expect, like how scientists can (and should) respond to the growing opioid addiction crisis – which has actually lowered life expectancy in America To register for this webinar, please visit the CDD website.

A Discussion with Chris Lipinski and Barry Bunin 2018-09-11T12:40:16+00:00

Bootcamp: Medicinal Chemistry (ESCMID/ASM 2018)

Antibiotic Bootcamps for Developers: Medicinal Chemistry ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 4-7 September 2018, Lisbon A collaborative project of GARDP and CARB-X Chair persons: John Griffin and Heinz Moser Speakers: Andrea Decker, Heinz Moser, John Griffin Roundtable discussion: Andrea Decker, Heinz Moser, John Griffin, John H. Rex Introduction Drug-Likeness: Physicochemical Properties in Small-Molecule Drug Discovery (Andrea Decker) Drug Discovery of Antibiotics: The Importance of Physicochemical Properties (Heinz Moser) Emerging Artificial Intelligence Approaches in Drug Discovery and their Application to Antibiotic Design (John Griffin) Roundtable discussion On 4 December, Heinz Moser will join us

Bootcamp: Medicinal Chemistry (ESCMID/ASM 2018) 2018-10-12T07:48:15+00:00


Antibacterial drugs: Clinical development for non-developers
Part 2: Development of antibacterial drugs targeting specific pathogens

Moderator: David Shlaes, Anti-infectives consulting, retired Speakers: Ian Friedland, Clinical consultant, Friedland Strategic Consulting, LLC Sumathi Nambiar, Director, Division of Anti-Infective Products, Office of Antimicrobial Products, CDER, FDA Mair Powell, Senior Clinical Assessor, Licensing Division, Medicines and Healthcare products Regulatory Agency (UK) The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products. Our first webinar was devoted to more traditional approaches (Tiers A and B), best suited for more broad-spectrum products, where the risks are lower. In this webinar, we discussed


Antibacterial drugs: Clinical development for non-developers
Part 2: Development of antibacterial drugs targeting specific pathogens
2018-10-01T09:41:35+00:00

Battle of the Bugs: Designing the Best Approach in the Fight Against Infectious Disease

Webinar on models for drug development programmes by Charles River: The emergence of antibiotic-resistant bacteria and genetic variance amongst viruses has embattled the development of effective treatment and vaccination against infectious diseases, leading to a worldwide crisis in medical care. This webinar will help you choose the correct models for your drug development program; from early in vitro screening assays providing identification of efficacy, to a range of clinically relevant in vivo models. We also explore the use of the Galleria mellonella (wax moth larvae) model as an additional early proof-of-concept model prior to in vivo testing, which

Battle of the Bugs: Designing the Best Approach in the Fight Against Infectious Disease 2018-07-05T14:44:06+00:00

PK-PD in support of accelerated programmes for antimicrobial development: how much is enough?

Speaker: William Hope, Centre of Antimicrobial Pharmacodynamics, University of Liverpool Moderator: Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna, Austria * This presentation was also part of the GARDP and CARB-X co-organized session 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th ECCMID in Madrid in April 2018. * In this webinar, William Hope talked about the role of pharmacokinetics and pharmacodynamics for antimicrobial drug development. He discussed the EMA guideline on the use of PK/PD and basic studies to inform dose finding strategies and also advised on realistic benchmarking, endpoints, and interpretation of study

PK-PD in support of accelerated programmes for antimicrobial development: how much is enough? 2018-10-01T09:39:04+00:00


Antibacterial drugs: Clinical development for non-developers
Part 1: Traditional development – tiers A and B

NEW: Download a summary of this webinar here! Speaker: David Shlaes - Anti-infectives consulting, retired Moderator: Laura Piddock - Head of Scientific Affairs, GARDP In this presentation we introduce the relationship between the discovery phase and later clinical development. We discuss in some depth traditional clinical development pathways (tiers A and B) focusing on the non-inferiority trial design. We hosted a live webinar with David Shlaes and Laura Piddock on June 13, 2018. If you have questions or comments, please let us know. Do so by posting them in our forum or submitting them via the 'Talk to an


Antibacterial drugs: Clinical development for non-developers
Part 1: Traditional development – tiers A and B
2018-10-01T09:42:40+00:00

Drug Discovery Data Insights: Highly Accessible SAR Data is Transforming the Drug Discovery Informatics Landscape

On June 26th, 2018, Collaborative Drug Discovery (CDD) hosted a webinar where moderator Ashley Farley, Associate Officer of Knowledge & Research Services at the Bill & Melinda Gates Foundation (BMGF) discussed drug discovery data with Dr. Andrew Leach from ChEMBL and Dr. Evan Bolton from PubChem. The presenters discussed the emergence of freely available PubChem and ChEMBL resources for chemical and biological Structure-Activity-Relationship (SAR) data and their impact on the global drug discovery informatics landscape. The relationship between chemical structure and biological activity is commonly referred as Structure Activity Relationship (SAR). SAR assessments are generated via computational tools,

Drug Discovery Data Insights: Highly Accessible SAR Data is Transforming the Drug Discovery Informatics Landscape 2018-07-05T14:02:47+00:00

Alternatives to (classical) antibiotics: what will it take to convincingly develop a virulence inhibitor or similar indirect agent?

John H. Rex Date : April 22, 2018 This presentation was part of the educational workshop: 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, April 21-24, 2018 Co-organized by: GARDP - Global Antibiotic Research Development Partnership, CARB-X - Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Chair persons: William Hope and Sumathi Nambiar Introduction: In order to speed up antibacterial development programmes it's important to be aware of the regulatory tools involved. PK-PD modelling and simulation can be

Alternatives to (classical) antibiotics: what will it take to convincingly develop a virulence inhibitor or similar indirect agent? 2018-07-31T08:53:03+00:00

PK-PD in support of accelerated programmes: how much is enough?

William Hope Date : April 22, 2018 This presentation was part of the educational workshop: 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, April 21-24, 2018 Co-organized by: GARDP - Global Antibiotic Research Development Partnership, CARB-X - Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Chair persons: William Hope and Sumathi Nambiar Introduction: In order to speed up antibacterial development programmes it's important to be aware of the regulatory tools involved. PK-PD modelling and simulation can be used

PK-PD in support of accelerated programmes: how much is enough? 2018-07-31T08:52:14+00:00

US regulatory tools for expedited antibacterial development programmes

Sumathi Nambiar Date : April 22, 2018 This presentation was part of the educational workshop: 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, April 21-24, 2018 Co-organized by: GARDP - Global Antibiotic Research Development Partnership, CARB-X - Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Chair persons: William Hope and Sumathi Nambiar Introduction: In order to speed up antibacterial development programmes it's important to be aware of the regulatory tools involved. PK-PD modelling and simulation can be used

US regulatory tools for expedited antibacterial development programmes 2018-07-31T08:50:48+00:00

EU regulatory tools for expedited antibacterial development programmes

Marco Cavaleri Date : April 22, 2018 This presentation was part of the educational workshop: 'Expediting antibacterial development: core lessons and key tools for a rocky road' at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, April 21-24, 2018 Co-organized by: GARDP - Global Antibiotic Research Development Partnership, CARB-X - Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Chair persons: William Hope and Sumathi Nambiar Introduction: In order to speed up antibacterial development programmes it's important to be aware of the regulatory tools involved. PK-PD modelling and simulation can be used

EU regulatory tools for expedited antibacterial development programmes 2018-07-31T08:50:10+00:00

Decisions, Decisions: What Makes a Good Hit? A Good Lead? Why Do You Write a TPP? How Do You Write a TPP?

Antibiotic Bootcamps for Developers A collaborative project of CARB-Xed, GARDP, ASM, and ESCMID 5-8 September 2017, ASM-ESCMID Conference, Boston Moderator: Lynn Silver, LL Silver Consulting, LLC Discussants:  Lynn Silver, LL Silver Consulting, LLC Tom Dougherty, Harvard Medical School John Tomayko, Infectious Diseases Consultant Sherman T. Waddell, Prokaryotics, Inc. Date : September 5th, 2017

Decisions, Decisions: What Makes a Good Hit? A Good Lead? Why Do You Write a TPP? How Do You Write a TPP? 2018-10-01T10:18:26+00:00

How Does a Molecule Become a Physical Medicine to be Given to a Human: The Importance of Chemistry, Manufacturing, and Controls

Antibiotic Bootcamps for Developers A collaborative project of CARB-Xed, GARDP, ASM, and ESCMID 5-8 September 2017, ASM-ESCMID Conference, Boston Moderator: Tim Keutzer, Spero Therapeutics Discussants: Tim Keutzer, Spero Therapeutics Evan Hecker, Spero Therapeutics Mike Young, Tedor Pharma Inc Andrew Barlow, Syner-G Pharma Consulting Date : September 5th, 2017

How Does a Molecule Become a Physical Medicine to be Given to a Human: The Importance of Chemistry, Manufacturing, and Controls 2018-10-01T10:21:13+00:00

Clinical Microbiology for a Development Program

Antibiotic Bootcamps for Developers A collaborative project of CARB-Xed, GARDP, ASM, and ESCMID 5-8 September 2017, ASM-ESCMID Conference, Boston Moderator: Judith Steenbergen, Paratek Pharmaceuticals Discussants: Erika Matuschek, EUCAST: Investigational New Drug - Groundwork for in vitro antimicrobial susceptibility testing Kevin Krause, Achaogen: NDA Requirements: Surveillance, Clinical Trial Data, Breakpoints Robin Patel, Mayo Clinic: Making Antibacterial Susceptibility Available in Clinical Practice Roundtable: Pitfalls in Development Date : September 5th, 2017

Clinical Microbiology for a Development Program 2018-10-01T10:22:57+00:00

Antoine Andremont

Antoine Andremont is currently Emeritus Professor at the Paris Diderot University Medical School, France, a scientific advisor at the French Ministry of Higher Education, Research and Innovation, and serves as an expert witness for the French National Highest Judiciary Court (Cour de Cassation). He is also the co-founder and a senior scientific advisor at biotechnology company Da Volterra - which he created in 2000 to research and understand the impact of antibiotics on the intestinal flora microbiota, the development and dissemination of bacterial resistance and the means to prevent it. Most of his career has been devoted to research in

Antoine Andremont 2018-08-29T11:29:12+00:00

John N van den Anker

John N van den Anker is a renowned paediatric consultant based at the Children’s National Medical Center Washington, DC, whose research has resulted in a much more evidence-based use of antibacterial agents such as aminoglycosides, cephalosporins, penicillins, meropenem, and vancomycin in children. John holds many titles including, the Evan and Cindy Jones Endowed Professor of Paediatric Clinical Pharmacology at Children’s National Medical Center; the Eckenstein-Geigy Distinguished Professor in Paediatric Pharmacology and Pharmacometrics at the University of Basel Children’s Hospital in Switzerland, and Adjunct Professor at Johns Hopkins University in Baltimore. He is also Adjunct Faculty Professor at the Erasmus Medical

John N van den Anker 2018-10-03T14:06:45+00:00

Jesús Rodríguez-Baño

Jesús Rodríguez-Baño is Professor of Medicine at the University of Seville and Head of the Infectious Diseases division at Hospital Universitario Virgen Macarena in Seville, Spain. He is also Scientific Chair of the Spanish Network for Research in Infectious Diseases (REIPI), which is funded by Instituto de Salud Carlos III, and President-Elect of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Jesús is a medical doctor and specialist in internal medicine, who gained his PhD in medicine in 1997 and expert degree in epidemiology and clinical research in 2000. He has since been a faculty member of the

Jesús Rodríguez-Baño 2018-03-13T08:16:28+00:00

Michael Barbachyn

Michael Barbachyn is the Brummel Chair and Professor of Organic Chemistry at Calvin College, Michigan, US, and an independent consultant at Barbachyn Consulting. Michael has over 27 years’ experience in medicinal chemistry as a research scientist following periods at Upjohn, Pharmacia & Upjohn, Bristol-Myers Squibb, Pharmacia, Pfizer and AstraZeneca, focused on anti-infectives. Michael also has 12 years’ pharmaceutical industry management experience as an associate director and director in antibacterial medicinal chemistry at Pharmacia and then Pfizer; and as a director and head of External Science, Infection Innovation Medicines, at AstraZeneca where he worked until 2012. That year he also joined

Michael Barbachyn 2018-03-26T07:54:34+00:00

Greg Basarab

Greg Basarab is Principal Research Officer and Associate Director at the University of Cape Town (UCT), Drug Discovery and Development Centre (H3D). He is Head of drug metabolism and pharmacokinetics (DMPK) and pharmacology groups located at Groote Schuur Hospital, Head of Institute of Infectious Diseases and Molecular Medicine, and Head of Medicinal Chemistry groups within the UCT Chemistry Department. He lectures at the UCT Medical School on Drug Disposition and Pharmacology. Greg worked in various aspects of antibacterial and antifungal infection research for over 30 years at AstraZeneca and Dupont. He was an Associate Director leading multiple discovery project teams

Greg Basarab 2018-03-12T13:20:21+00:00

Alex van Belkum

Alex van Belkum is currently Scientific Director of Microbiology Research at bioMérieux, a diagnostics company based in the South of France. He is also a fellow of the American Academy of Microbiology. Alex is a microbiologist in the data analytics unit of bioMérieux with a prime interest in next generation sequencing, and the use of other data-rich technologies in clinical microbiology. His long career has been dedicated to the research of molecular epidemiology, molecular and culture-based diagnostics and antimicrobial resistance testing in clinical microbiology. Alex has authored more than 530 PubMed-cited papers and has an H-index of 89. He has

Alex van Belkum 2018-08-29T13:54:05+00:00

Julia Bielicki

Julia Bielicki is currently a consultant in Paediatric Infectious Diseases and Infection Prevention and Control at the University of Basel Children’s Hospital. She is also an active researcher with the Paediatric Pharmacology Division at the University of Basel Children’s Hospital and a Senior Lecturer with the Paediatric Infectious Diseases Research Group at St George’s University of London. Furthermore, Julia is involved in developing a national antimicrobial stewardship programme in Switzerland. Julia’s research focuses on observational and interventional studies that aim to improve the use of antibiotics to treat neonates and children - in the light of an increasing burden of

Julia Bielicki 2018-10-09T12:12:44+00:00

Helen W Boucher

Helen Boucher is currently Director of the Infectious Diseases Fellowship Program, Director of the Heart Transplant and Ventricular Assist Device Infectious Diseases Program, and staff physician in the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center. She is also Professor of Medicine at Tufts University School of Medicine in Boston, Massachusetts. Helen trained as a medical doctor at the University of Texas Medical School, Houston, before completing her internship, residency and chief residency in Internal Medicine at the New England Deaconess Hospital, and her clinical and research fellowships in infectious diseases at the Beth Israel Deaconess Medical

Helen W Boucher 2018-03-09T12:32:06+00:00

Pamela Brown

Pamela Brown has over 30 years’ experience in anti-infective drug discovery gained within the biotech and pharmaceutical sectors. She is currently a consultant in Antibacterial Drug Discovery and Medicinal Chemistry offering independent advice and expertise to small and medium-sized enterprises (SMEs), biotechs and academic institutions. Pam was Director, Medicinal Chemistry at Cantab Anti-infectives for five years following its inception in 2012. There, Pam led the medicinal chemistry team towards novel polymyxins, resulting in a commercial deal with Spero Therapeutics in 2016, and the selection of a preclinical candidate in 2017. Before joining Cantab, she was Director, Medicinal Chemistry at Novacta

Pamela Brown 2018-03-08T14:01:34+00:00

Karen Bush

Karen Bush is a PhD graduate in biochemistry from Indiana University (IU). She spent 36 years in pharmaceutical research before joining the IU faculty to continue her focus on antibiotic drug discovery and development, based on her research on antibiotic resistance mechanisms. Karen’s major research has been in the area of beta-lactamases, the enzymes primarily responsible for antibiotic resistance to penicillins and cephalosporins and she has been a leader in beta-lactamase characterization and nomenclature. Karen’s research group has studied the mode of action of beta-lactamases and their interactions with beta-lactams. Her laboratory has collaborated with other investigators to characterize key

Karen Bush 2018-03-09T14:47:21+00:00

Vincent Cattoir

Vincent Cattoir is currently Professor of Clinical Microbiology at the University of Rennes 1, as well as a clinical microbiologist at the Bacteriology department of the University Hospital of Rennes, France. Vincent is the Director of the Lab Enterococci, affiliated to the National Reference Center for Antimicrobial Resistance. He is also a senior scientist in the INSERM U1230 Pharmaceutical Biochemistry at the University of Rennes 1, currently focused on regulator RNAs (sRNAs) involved in the pathogenicity and antimicrobial resistance in opportunistic bacterial species such as Enterococcus faecium and Enterobacter cloacae. Since completing his residency in clinical microbiology at the Henri

Vincent Cattoir 2018-08-30T07:54:24+00:00

Ryan Cirz

Ryan Cirz is Vice President of Infectious Disease Research and Head of the Postdoctoral Program at Achaogen, which focuses on discovering, developing and commercializing innovative antibacterials to treat multi-drug resistant (MDR) Gram-negative infections. Ryan has worked on antibacterial discovery and development at Achaogen for 11 years in roles of increasing seniority, focused almost exclusively on new agents for MDR Gram-negative pathogens. He currently oversees the progress of Achaogen’s early-stage (pre-investigational new drug) pipeline and provides intellectual insight/support to all things related to infectious diseases including late stage development, commercialization and medical affairs. Ryan has a background in molecular biology and

Ryan Cirz 2018-03-26T07:58:45+00:00

Anthony Coates

Anthony Coates is the Founder and Chief Scientific Officer of Helperby Therapeutics, a biopharmaceutical company dedicated to developing the next generation of lifesaving antibiotics. Anthony created the company in 2002 and together with colleague Yanmin Hu invented Antibiotic Resistance Breakers (ARBs), a new form of ‘antibiotic renewable’ technology. With existing antibiotic treatments rapidly becoming obsolete, Helperby’s unique antibiotic technology outsmarts highly resistant bacteria by combining ARBs with old antibiotics such as colistin, to create a new and sustainable commercially viable generation of therapies. Helperby’s latest potential therapy, azidothymidine and low-dose colistin, is one of only a handful of drug candidates

Anthony Coates 2018-10-03T12:00:24+00:00

Matthew Cooper

Matthew Cooper is co-founder, Director and Chief Executive Officer of Inflazome, which develops inflammasome inhibitors for chronic inflammatory diseases. Matt is also Co-Founder and Director of Defensin Therapeutics and Affiliate Professor at Trinity College Dublin. He holds a fractional Professorial Research Fellow appointment at the University of Queensland, where he is Professor of Chemical Biology at the Institute of Molecular Bioscience and, Affiliate Professor in the School of Chemistry and Molecular Biology. Matt obtained his PhD in 1995 in organic chemistry, and a BSc from the University of Adelaide, Australia, before moving to the UK. In the UK he was

Matthew Cooper 2018-07-03T07:52:51+00:00

Patrice Courvalin

Professor Patrice Courvalin is an internationally recognized expert in the genetics and biochemistry of antibiotic resistance, and in the transfer and heterologous expression of genetic information. He first described and then elucidated, vancomycin resistance in Enterococcus. Patrice’s research has led to a revision of the dogma describing natural dissemination of antibiotic-resistance genes. He and his colleagues demonstrated that a wide variety of pathogenic bacteria can promiscuously exchange genetic material, and proved that conjugation could account for dissemination of genes between phylogenetically remote bacterial genera. The group has also elucidated the transposition mechanism of conjugative transposons from Gram-positive cocci, and more

Patrice Courvalin 2018-03-12T13:24:47+00:00

Mike Dawson

Mike Dawson is a consultant in antimicrobial research, who has spent the last 14 years working in the biotech sector. Mike also has over 20 years’ experience in the pharmaceutical industry gained at GSK. As Head of Biotransformation and Natural Product Chemistry he played leading roles in natural product based drug discovery and the application of biological processes to drug manufacturing. He left GSK in 2003 to set up Novacta Biosystems where, as Chief Scientific Officer (CEO), he led the development of the company's C. difficile programme (NVB302) to a successful phase I clinical trial. Mike became CEO of Cantab

Mike Dawson 2018-03-08T14:14:35+00:00

George L Drusano

George Drusano is director of the Institute for Therapeutic Innovation at the University of Florida, whose mission is to improve the therapy for serious infectious diseases. After graduating magna cum laude from the honours programme at Boston College, George graduated cum laude from the University of Maryland School of Medicine in Baltimore. He completed his medical internship and residency at the University of Maryland Hospital, where he was also Chief Medical Resident and a Fellow in Medicines in Infectious Diseases. George was a Professor at the University of Maryland, Head of the Division of Clinical Pharmacology at Albany Medical College

George L Drusano 2018-03-08T14:30:28+00:00

Jacques Dumas

Jacques Dumas is a trained chemist with over 20 years’ experience in discovery to clinical proof-of-concept in infectious diseases and oncology. He has been Chief Scientific Officer (CSO) of Tetraphase Pharmaceuticals since July 2015, where he oversees non-clinical sciences and CMC (Chemistry, Manufacturing and Controls) activities to support the company’s product pipeline. Jacques became CSO at Idenix Pharmaceuticals in January 2014, then Vice President at Merck following Merck’s acquisition of Idenix. Between 2007 and 2014, Jacques held several positions at AstraZeneca, most latterly as Vice-President and Head of Strategy, Infection Innovative Medicines. In this role, he was responsible for disease

Jacques Dumas 2018-03-12T07:45:59+00:00

Barry I Eisenstein

Barry Eisenstein is the chair of the Scientific and Business Advisory Board of CARB-X, a public-private partnership based at Boston University, devoted to new antimicrobial drug and diagnostic development. Barry received his medical degree from Columbia University and subsequently trained in internal medicine and infectious diseases at the University of North Carolina. He has spent his career in academy and industry, serving as Chief of the Infectious Diseases division at the University of Texas Health Science Center, San Antonio then as Professor and Chair of the Department of Microbiology and Immunology at the University of Michigan. Following four years as

Barry I Eisenstein 2018-03-09T07:08:05+00:00

Alice Erwin

Alice Erwin is an independent scientific consultant, providing advice on antibiotic discovery to academic and industrial research groups. She also conducts due-diligence evaluation of antibacterial programmes being evaluated as in-licensing or investing opportunities. Alice is an infectious disease microbiologist with experience in both academic and industrial settings. Her scientific research over the past thirty years has revolved around the structure and function of bacterial membranes, with particular interest in the contribution of lipopolysaccharides to both the pathogenesis and the intrinsic antibiotic resistance of Gram-negative bacteria. She held senior positions in programmes at PathoGenesis Corporation, Chiron Corporation, and Vertex Pharmaceuticals -

Alice Erwin 2018-08-29T12:18:21+00:00

Domingo Gargallo-Viola

Domingo Gargallo-Viola is a co-founder and Chief Scientific Officer at ABAC Therapeutics, a leader in pathogen-specific antibiotics that was formerly part of Grupo Ferrer Internacional based in Spain. Domingo has over 30 years’ experience in the discovery and development of anti-infective drugs. At ABAC Therapeutics he is focused on the discovery and development of first-in-class, novel mechanism of action, pathogen-specific, narrow spectrum antibiotics - for the treatment of severe and life-threatening infections due to multidrug-resistant organisms. He is also responsible for the pipeline management, selection and coordination of external relationships with institutional organizations. He is former project leader and currently

Domingo Gargallo-Viola 2018-03-13T12:16:35+00:00

Olga Genilloud

Olga Genilloud, Scientific Director and Head of the Microbiology Department at Fundación MEDINA, has over 25 years’ extended research experience in the discovery and biosynthesis of novel natural products antibiotics, obtained in the academic, clinical environment and pharmaceutical sectors. Olga has a PhD in chemistry from the Complutense University of Madrid and has a solid background in industrial microbiology - with expertise in bacterial natural products, molecular biology, ecology and taxonomy, physiology, and production of secondary metabolites. Since 2009, Olga has led the discovery efforts at Fundación MEDINA, a non-profit public-private research company she helped set-up from the former R&D

Olga Genilloud 2018-03-16T10:48:28+00:00

Mark J Goldberger

Mark Goldberger is an independent consultant at Mark Goldberger MD MPH LLC Maryland, USA, where he advises pharmaceutical and biotech companies on the development of infectious diseases products. Before retiring in 2014 and becoming a consultant, Mark spent seven years at AbbVie - formerly part of Abbott - in various senior positons including vice president of regulatory affairs and senior advisor. In these roles he provided regulatory guidance and strategic advice with a focus on US Food and Drug Administration (FDA) and European Medicines Agency (EMA) activities and submissions. While at Abbott/AbbVie, Mark was involved in product and policy development,

Mark J Goldberger 2018-03-27T12:07:07+00:00

Trudy Grossman

Trudy Grossman is Senior Director of Biology and Pharmacology at Melinta Therapeutics in New Haven, Connecticut, where she manages a team supporting antibiotic discovery and development. Trudy has worked in microbiology in increasing roles of seniority for over 25 years; most of that time applying the genetics, molecular biology, physiology, and biochemistry of bacteria to the discovery and development of new anti-infectives. This includes tenures at several pharmaceutical companies including Lederle Laboratories where she discovered new genes essential for iron-transport in bacteria which could serve as novel anti-virulence targets in Gram-positive pathogens. While working at Procept Inc, Trudy discovered a

Trudy Grossman 2018-10-03T13:24:28+00:00

Bob Hancock

Bob Hancock is a leading microbiologist in Canada, who has researched and taught at the University of British Columbia (UBC) for nearly 40 years. Bob is currently UBC Killam Professor of Microbiology and Immunology, an Associate Faculty Member at the Wellcome Trust Sanger Institute in the UK, and a Canada Research Chair in Health and Genomics. Bob is focused on designing new therapeutic strategies to treat infections - in the light of increasing antibiotic resistance and a dearth of new antibiotic discovery. His research interests include small cationic peptides as novel antimicrobials and modulators of innate immunity, the development of

Bob Hancock 2018-03-12T13:58:07+00:00

Stephen Hawser

Stephen is Chief Executive Officer of IHMA Europe Sàrl based in Switzerland, a wholly owned affiliate of International Health Management Associates. Since it began operating in 2009, under Stephen’s leadership, IHMA has focused on providing a full suite of technical capabilities and domain expertise in all phases of antimicrobial drug development: drug discovery, clinical development, regulatory approval and commercialization. Before joining IHMA, Stephen held several key positions in the pharmaceutical industry spanning 15 years, focused on antibacterial and antifungal research and development. Stephen has worked at Arpida, GlaxoWellcome, Hoechst Marion Roussel and Marion Merrell Dow. Stephen has either written or

Stephen Hawser 2018-03-26T08:12:05+00:00

Paul Heath

Paul Heath is a Professor and Honorary Consultant in Paediatric Infectious Diseases at St George's University Hospital’s NHS Foundation Trust and St George’s, University of London, where he co-leads the Paediatric Infectious Diseases Research Group and is the Director of the Vaccine Institute. Before joining St George’s, Paul was a research fellow in the Oxford Vaccine Group Department of Paediatrics, at John Radcliffe Hospital, Oxford. Paul’s research has focused on the epidemiology of vaccine-preventable diseases, and clinical vaccine trials, particularly in at-risk groups, and in perinatal infections. He has published more than 230 articles in these areas. He coordinates a

Paul Heath 2018-10-03T12:13:42+00:00

William Hope

William Hope is Professor of Therapeutics and Infectious Diseases at the University of Liverpool in the UK where he also leads the newly formed Centre for Antimicrobial Pharmacodynamics (CAP). Being part of the university’s Institute of Translational Medicine, this centre provides the pharmacodynamic packages for the development for new antimicrobial agents. William qualified in medicine in 1991, before undertaking specialist training in infectious diseases and clinical microbiology. He completed his PhD in antimicrobial pharmacology in 2006, while undertaking fellowships at the University of Manchester, UK, and the National Institutes of Health, Bethesda, USA. He received a National Institute for Health

William Hope 2018-07-03T11:12:16+00:00

Deborah Hung

Deborah Hung is a trained physician, chemist and geneticist. She is currently an associate professor in the Department of Molecular Biology at Massachusetts General Hospital and in the Department of Genetics at Harvard Medical School. She is Director of the Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, an infectious disease physician at Brigham and Women’s Hospital and Massachusetts General Hospital and is an attending critical care physician in the Medical Intensive Care Unit at Brigham and Women’s Hospital. Deborah combines chemical and genomic approaches to define host-pathogen interactions and to reveal essential in vivo gene functions

Deborah Hung 2018-03-08T15:19:10+00:00

Khalid Islam

Khalid Islam is the owner of Life Sciences Management GmbH, which consults with start-ups, emerging biotechs and pharma on drug discovery and development. He is also a founding partner of Sirius Healthcare Partners, an advisory boutique in the healthcare sector. Khalid is the Chairman of the Board of Directors of Fennec Pharma and Minoryx Therapeutics, a member of the Board of Directors of Immunomedics and an advisor to the Paris-based venture group Kurma Biofund. Khalid has over 30 years’ experience in the pharmaceutical and biotechnology industry. He has been the chairman and chief executive officer (CEO) of Gentium where he led

Khalid Islam 2018-03-26T11:27:44+00:00

Nachum Kaplan

Nachum Kaplan is a co-founder of Nobelex Biotech and has been the Chief Scientific Officer (CSO) since its inception in 2014. Nachum leads on the discovery of new drugs, including overseeing antibacterial compound progression relative to milestone criteria and target product profiles. Nachum is also responsible for all in vitro microbiology studies, in vivo efficacy models and pharmacokinetic/pharmacodynamics (PK/PD) modelling. Before creating Nobelex, Nachum was CSO of Affinium Pharmaceuticals, a drug discovery and development company focused on novel antibiotic therapeutics. There he led the in vitro microbiology studies, in vivo efficacy studies and PK/PD, early preclinical and investigational new drug-enabling

Nachum Kaplan 2018-03-08T15:05:49+00:00

Sushmita Lahiri

Sushmita Lahiri is Executive Director of Biology at Macrolide Pharmaceuticals, a company focused on the discovery and development of novel synthetic macrolides that can be administered both intravenously and orally for the treatment of infections caused by multidrug-resistant Gram-negative pathogens. She is responsible for the strategy and execution of the microbiology and pharmacology pre-clinical studies. Before joining Macrolide, Sushmita worked in AstraZeneca’s infection division in Boston, USA, on the discovery and development of a broad range of antibacterial compounds including various diazabicyclooctane (DBO) β-lactamase inhibitors. This included avibactam and ETX-2514, in combination with multiple β-lactam partner drugs, as well as

Sushmita Lahiri 2018-08-29T14:19:16+00:00

Jennifer Leeds

Jennifer Leeds is Executive Director and Head of Antibacterial Discovery in the infectious diseases area of the Novartis Institutes for Biomedical Research (NIBR). She is responsible for the strategy and execution of the new antibacterial portfolio from target discovery through pre-clinical validation, and the clinical microbiology strategy and resources in clinical development. Jennifer co-invented and co-led the international discovery project team for the novel antibacterial LFF571, which demonstrated safety and efficacy in humans for the treatment of C. difficile infection. In June 2017, the NIBR antibacterial discovery group disclosed the preclinical discovery programme for LYS228, a novel antibacterial in phase

Jennifer Leeds 2018-03-09T14:40:05+00:00

David Lewis

David Lewis is currently the Director of Western Sydney Sexual Health Centre and conjoint Professor at the University of Sydney, Australia. Throughout his career, David has had a special interest in the clinical, microbiological and public health aspects of sexually transmitted infections (STIs) and HIV. David graduated as a medical doctor from the London Hospital Medical College, London University in 1987. Following senior house officer positions in general medicine, haematological oncology, infectious diseases, genitourinary and HIV medicine, David underwent specialist training in both microbiology and genitourinary and HIV medicine. His PhD focused on the pathogenesis of Haemophilus ducreyi infection and

David Lewis 2018-08-29T12:29:56+00:00

Jian Li

Jian Li is Head of the Antimicrobial Systems Pharmacology Laboratory at the Biomedicine Discovery Institute, Monash University in Melbourne, Australia. He has also been a Web of Science Highly Cited Researcher in Pharmacology and Toxicology since 2015. Jian has an internationally recognised track record in the pharmacology of polymyxins and the discovery of novel, safer polymyxins. The majority of modern polymyxin pharmacology data were reported by his research group which has led to the first scientifically-based dosing recommendations for intravenous colistin in critically-ill patients. His latest research led him to pioneer the integration of systems pharmacology into antimicrobial pharmacokinetics/pharmacodynamics for

Jian Li 2018-10-09T12:38:09+00:00

Sergio Lociuro

Sergio Lociuro is Chief Scientific Officer (CSO) at BioVersys AG where he leads the research and development of novel chemical entities that, upon binding to bacterial transcription regulators, are able to control/inhibit expression of resistance to given antibiotic classes, biofilm formation and virulence factors. Sergio has over 30 years’ experience in applied sciences and drug discovery gained in academia and pharma. He has held several positions in small and large pharmaceutical companies, such as a scientific coordinator at MMD (Lepetit), Director of Medicinal Chemistry and International Project Leader at GSK, Head of Peptide Epitope Mimetics in Polyphor, Head of Research

Sergio Lociuro 2018-03-09T13:10:50+00:00

Alexander Mankin

Alexander Mankin is Distinguished Professor and Director of the Center for Biomolecular Sciences at the University of Illinois at Chicago (UIC), USA. He also holds the title of A. Neyfakh Collegiate Professor at the College of Pharmacy, UIC. Alexander’s research focuses on the mechanisms of action of ribosomal antibiotics. Through research carried out by his laboratory and collaborations with pharmaceutical companies, he has helped identify the sites and modes of action of several important classes of antibacterials, including oxazolidinones, ketolides, odilorhabdins, and others. Studies carried out by his laboratory have re-defined how people understand how antibiotic classes such as macrolides

Alexander Mankin 2018-10-03T14:13:30+00:00

Jeanne Marrazzo

Jeanne Marrazzo is Professor of Medicine and Director of the Division of Infectious Diseases at the University of Alabama, Birmingham, USA. She is internationally recognized for her research and education efforts in the field of sexually transmitted infections (STIs), especially as they affect women’s health. She is a fellow of the American College of Physicians and of the Infectious Diseases Society of America. She is board certified in infectious diseases. Jeanne conducts research on the human microbiome, specifically as it relates to female reproductive tract infections and hormonal contraception. Her other research interests include the prevention of HIV infection using

Jeanne Marrazzo 2018-08-29T13:03:33+00:00

Alita Miller

Alita Miller is a Senior Director and Head of Bioscience at Entasis Therapeutics, a small biotech outside of Boston, USA, dedicated to the discovery and development of novel antibacterial agents to treat serious infections by resistant Gram-negative bacteria. At Entasis, Alita oversees both preclinical biology and developmental microbiology research. As a member of the senior leadership team, she is also involved in the strategic planning and execution of the company’s long-term research objectives. Alita has over 15 years’ experience in antibacterial research, first at Pfizer where she led both large and small molecule discovery projects and then at AstraZeneca, where

Alita Miller 2018-08-29T13:14:22+00:00